Search Results
Your search for ,kEY matches 7151 pages
Showing 301 - 350Non–Total Body Irradiation Conditioning Regimen for Young Patients With MRD-Negative B-ALL
Two-year event-free survival rates were above 75% for children, adolescent, and young adult patients with B-cell acute lymphocytic leukemia (B-ALL) who had negative measurable residual disease (MRD) by next-generation sequencing prior to hematopoietic cell transplantation and who received a...
Cyclophosphamide-Based Strategy Enables Safe Transplant From Broadly Mismatched Donors
Clinicians have traditionally prioritized high-level human leukocyte antigen (HLA) matching to minimize graft-vs-host disease (GVHD) after hematopoietic cell transplantation (HCT). New data from the ACCESS study, sponsored by the National Marrow Donor Program, indicate that the use of...
Building the Cancer Care Africa Deserves
There is something deeply moving about watching hope take shape, not as a slogan or a speech, but as people coming together to build the cancer care Africa deserves. The African Organization for Research and Training in Cancer (AORTIC) 2025 Congress in Tunisia held in November was a vivid reminder...
Validation of Pathology-AI Integration Tool for Risk Stratification in Locally Advanced Colon Cancer Without Chemotherapy
The Combined Analysis of Pathology and Artificial Intelligence (AI; CAPAI) model effectively stratified patients with colon cancer into distinct prognostic groups, identifying nearly half as low-risk, with “favorable” cancer-specific survival outcomes in the absence of adjuvant chemotherapy,...
New Pooled Analysis Strengthens Case for MRD as Surrogate Endpoint in AML
Measurable residual disease (MRD), regardless of the method of assessment, is a robust individual-level predictor for overall survival among patients with acute myeloid leukemia (AML) who have already received induction therapy, according to findings from a pooled analysis presented at the 2025...
Benefits Mount for TROP2-Directed Antibody-Drug Conjugates in Triple-Negative Breast Cancer
Two randomized phase III trials presented at the European Society for Medical Oncology (ESMO) Congress 2025 bolster support for the use of antibody–drug conjugates—in particular, trophoblast cell surface antigen 2 (TROP2)-targeted agents—as first-line treatments for patients with triple-negative...
Fixed-Duration Doublet Noninferior to Continuous Ibrutinib in CLL
Early results from the CLL17 trial show that fixed-duration doublet regimens with venetoclax are noninferior to continuous ibrutinib therapy, with similar 3-year progression-free survival rates, for patients with chronic lymphocytic leukemia (CLL), according to findings presented at the 2025...
Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining) unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer,...
Final Overall Survival Confirms Benefit of Durvalumab Plus FLOT in Resectable Gastric and Gastroesophageal Junction Adenocarcinomas
The addition of the PD-L1–targeting monoclonal antibody durvalumab to conventional perioperative chemotherapy with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) resulted in a statistically significant and clinically meaningful improvement in overall survival, with benefit seen...
Sacituzumab Tirumotecan Improves Survival in EGFR-Mutated NSCLC After Tyrosine Kinase Inhibitor Failure
Sacituzumab tirumotecan, a novel TROP2 antibody-drug conjugate, was found to significantly improve both progression-free and overall survival compared with platinum-based chemotherapy in patients with EGFR-mutated non–small cell lung cancer (NSCLC) who had experienced disease progression following...
LuPSMA-617 Plus Hormone Therapy Improves Radiographic Progression–Free Survival in Metastatic Hormone-Naive Prostate Cancer
The addition of lutetium-177–labeled PSMA-617 (vipivotide tetraxetan; LuPSMA-617), a targeted radionuclide therapy, to standard-of-care androgen-deprivation therapy and an androgen receptor pathway inhibitor appeared to significantly improve radiographic progression–free survival in patients with...
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
Camrelizumab Plus Rivoceranib vs Sorafenib for the First-Line Treatment of Unresectable Hepatocellular Carcinoma
As reported in The Lancet Oncology by Qin et al, the final analysis of the phase III CARES-310 trial has shown superior overall survival with camrelizumab plus rivoceranib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. Initial reports from the study...
Total Neoadjuvant Therapy and Nonoperative Management in pMMR/MSS Stage II to III Rectal Cancer
In an Italian phase II trial (NO-CUT) reported in The Lancet Oncology, Amatu et al found that total neoadjuvant therapy followed by nonoperative management in cases of complete response resulted in promising outcomes in patients with proficient mismatch repair or microsatellite stable (pMMR/MSS)...
Fuzuloparib in HER2-Negative Metastatic Breast Cancer With Germline BRCA1/2 Mutations
In an interim analysis of a Chinese phase III trial (FABULOUS) reported in The Lancet Oncology, Li et al found that the addition of the PARP inhibitor fuzuloparib to apatinib and fuzuloparib alone improved progression-free survival vs chemotherapy in patients with HER2-negative metastatic breast...
Mammography-Based Outreach Increases Lung Cancer Screening Enrollment in Eligible Women
Women who undergo mammography to screen for breast cancer can be reviewed and recommended for additional lung cancer screening, thereby increasing enrollment, according to the results of a study published in the Journal of the American College of Radiology. The study, called Coordinate a Lung...
Are Glycemic Index and Load Associated With Lung Cancer Risk?
Based on the results of a population-based cohort study published in Annals of Family Medicine by Wang et al, high dietary glycemic index is linked to increased risks of lung cancer, non–small cell lung cancer (NSCLC), and small cell lung cancer (SCLC), whereas glycemic load is inversely associated ...
Upfront Reduced-Dose Enfortumab Vedotin With Pembrolizumab in First-Line Treatment of Advanced Urothelial Cancer
In a U.S. retrospective cohort study reported in JAMA Oncology, Chow et al found that reduced-dose vs standard upfront enfortumab vedotin-ejfv plus pembrolizumab reduced the risk of enfortumab vedotin treatment interruption in the first-line treatment of patients with advanced urothelial cancer....
Pancreatic Cancer Detection: AI vs Radiologists
In a study (PANORAMA) reported in The Lancet Oncology, Alves et al found that an artificial intelligence (AI) program developed by the investigators was significantly better at detecting pancreatic ductal adenocarcinoma when applied to standard-of-care computed tomography (CT) scans than were...
Second-Line Pembrolizumab Plus Lenvatinib in Pleural Mesothelioma
In a cohort of a Dutch single-center phase II study (PEMMELA) reported in The Lancet Oncology, Douma et al found that pembrolizumab plus lenvatinib was active in patients with pleural mesothelioma whose disease progressed after treatment with nivolumab plus ipilimumab. In cohort 1 in the trial,...
Lung Cancer Deaths Prevented and Life-Years Gained From Lung Cancer Screening: Current vs 100% Screening Uptake
In a study reported as a research letter in JAMA, Bandi et al compared estimated deaths prevented and life-years gained with current uptake vs 100% uptake of annual lung cancer screening in eligible U.S. individuals. Study Details The study used data obtained from the 2024 National Health Interview ...
Nivolumab and Ipilimumab in Advanced dMMR/MSI-H Noncolorectal Cancers
In an Australian and New Zealand phase II trial (MOST-CIRCUIT) reported in JAMA Oncology, Carlino et al found that combined anti–PD-1/CTLA-4 blockade was associated with a high rate of durable responses in patients with advanced mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) ...
AYA Cancers: Survival for Metastatic Recurrence Worse Than De Novo Metastatic Disease
Almost 10% of adolescents and young adults (AYAs) diagnosed with earlier-stage cancer develop metastatic disease, and survival outcomes were found to be worse for patients who developed metastatic recurrence compared with those who had metastatic disease at initial diagnosis for almost all analyzed ...
Retrospective Review Shows Persistent Breast Cancer Burden in Younger Women
Up to 24% of breast cancers diagnosed in an 11-year period between seven outpatient facilities around New York were found in women aged 18 to 49 years, according to findings presented during the 2025 Annual Meeting of the Radiological Society of North America (RSNA; Abstract S5-SSBR02-1). “This...
Addition of Neoadjuvant LuPSMA PNT2002 to SBRT in Oligorecurrent Prostate Cancer
In a single-center phase II trial (LUNAR) reported in the Journal of Clinical Oncology, Kishan et al found that the addition of neoadjuvant prostate-specific membrane antigen (PSMA)-targeting radioligand therapy with lutetium-177–labeled PNT2002 (LuPSMA PNT2002) to stereotactic body radiotherapy...
Tisagenlecleucel in Relapsed or Refractory Large B-Cell Lymphoma: 5-Year Outcomes From the JULIET Trial
As reported in the Journal of Clinical Oncology by Maziarz et al, 5-year analysis of the pivotal phase II JULIET trial has shown maintained efficacy of tisagenlecleucel in patients with relapsed or refractory large B-cell lymphoma. Study Details In the trial, 115 patients received tisagenlecleucel...
Is Chronic Hepatitis C Infection Associated With Pancreatic Cancer?
A retrospective, national, population-based cohort study of 6.3 million veterans, which was published in JAMA Network Open, found that individuals with chronic hepatitis C virus developed pancreatic ductal adenocarcinoma at younger ages and had a higher risk compared with those without the...
Image-Only AI Model Outperforms Breast Density Assessment for 5-Year Breast Cancer Risk Stratification
An image-only artificial intelligence (AI) model demonstrated stronger and more precise risk stratification than breast density assessment for predicting 5-year risk for developing breast cancer, according to findings from a study presented at the 2025 Annual Meeting of the Radiological Society of...
Exploratory FLAURA2 Analysis Confirms Overall Survival Benefit for Osimertinib in NSCLC Subgroups
An exploratory overall survival analysis of the phase III FLAURA2 trial confirmed the overall survival benefit of adding osimertinib to chemotherapy in patients with non–small cell lung cancer (NSCLC) and mutations in the epidermal growth factor receptor (EGFR) not previously treated for advanced...
ADCs vs Standard Chemotherapy: Cardiotoxicity in HER2-Positive Advanced Breast Cancer
A systematic review and meta-analysis published in JAMA Network Open compared the cardiotoxicity of novel antibody-drug conjugates (ADCs) with that of standard trastuzumab-containing chemotherapy in patients with HER2-positive locally advanced or metastatic breast cancer, finding that treatment...
First-Line Treatment in RAS Wild-Type Metastatic Colorectal Cancer: Outcomes Associated With Consensus Molecular Subtypes
In an individual patient meta-analysis reported in the Journal of Clinical Oncology, Stahler et al identified outcomes associated with consensus molecular subtypes (CMSs) in patients undergoing first-line treatment for RAS wild-type metastatic colorectal cancer. Study Details Individual patient...
Addition of Pirfenidone to Glucocorticoids in Grade 2 or 3 Radiation-Induced Lung Injury
In a Chinese phase II trial reported in The Lancet Oncology, Hou et al found that the addition of the antifibrotic pirfenidone to glucocorticoid treatment significantly improved the carbon dioxide diffusing capacity (DLCO%) in patients with grade 2 or 3 radiation-induced lung injury. Study Details...
Lung Cancer Screening Criteria: NELSON vs PLCOm2012
In a German study (HANSE) reported in The Lancet Oncology, Vogel-Claussen et al found that the PLCOm2012 low-dose computed tomography (CT) lung cancer screening eligibility criteria were more effective than the NELSON criteria in the detection of lung cancer. Study Details The prospective cohort...
External Validation Confirms Ability of AI Model to Stratify Recurrence Risk in Early-Stage Lung Cancer
A machine learning–based survival model, incorporating preoperative CT images and routinely available clinical data, outperformed standard clinical staging systems in predicting recurrence after surgery in patients with lung cancer, especially in stage I, and showed correlations with established...
No Overall Survival Benefit for Lenvatinib in LEAP-014 Trial of Esophageal Cancer
For the first-line treatment of metastatic esophageal squamous cell carcinoma, the addition of lenvatinib to pembrolizumab and chemotherapy failed to improve overall survival over pembrolizumab plus chemotherapy in the phase III LEAP-014 trial, as reported at the European Society for Medical...
AI Simplifies Patients' Comprehension of CT Reports—but Errors Are Possible
Simplified oncologic computed tomography (CT) reports using large language models (LLMs) enabled patients to better understand the results of their restaging CT scans and reduced overall reading burden, according to the results of a study published in Radiology. However, the study also revealed...
Memorial Sloan Kettering Names Recipients of 2025 Paul Marks Prize for Cancer Research
Memorial Sloan Kettering Cancer Center (MSK) will award three cancer researchers with this year’s Paul Marks Prize for Cancer Research. The prize, named in honor of former MSK president Paul Marks, MD, recognizes a new generation of leaders who are making significant contributions to the...
Significant Medicare Physician Reimbursement Methodology Changes Finalized for 2026
The Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician Fee Schedule final rule for 2026 on October 31, 2025.1 The rule finalizes physician reimbursement and policy reforms under the Physician Fee Schedule as well as changes to reporting requirements and policy...
Project DISARM: New Cancer Mission Emphasizes Risk Assessment and Early Detection of Ovarian Cancer
Often referred to as a “silent killer,” ovarian cancer is the most lethal of female cancers. Issues of late detection and poor survival rates continue to persevere, leading to increasing levels of incidence and mortality. Data from the World Ovarian Cancer Coalition have stressed that ovarian...
Zanzalintinib Plus Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer
The phase III STELLAR-303 trial evaluated the anti-VEGFR–related multitargeted tyrosine kinase inhibitor zanzalintinib in combination with the PD-L1 inhibitor atezolizumab vs the multikinase inhibitor regorafenib in patients with previously treated non–microsatellite instability (MSI)–high...
Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC
In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizumab-jsgr plus chemotherapy, a 40% reduction in risk as first-line treatment of advanced squamous...
Treatment Advances in Malignant Hematology: 2025 Updates
The pace of therapeutic innovation in hematologic oncology continues to accelerate, moving clinical practice away from broad-spectrum chemotherapy and toward an era of highly personalized, biologically driven treatment. This transformation was the central theme of the 2025 National Comprehensive...
LuPSMA-617 Plus Hormone Therapy Improves Radiographic Progression–Free Survival in Metastatic Hormone-Naive Prostate Cancer
The addition of lutetium-177–labeled PSMA-617 (vipivotide tetraxetan; LuPSMA-617), a targeted radionuclide therapy, to standard-of-care androgen-deprivation therapy and an androgen receptor pathway inhibitor appeared to significantly improve radiographic progression–free survival in patients with...
Primary Analysis Shows Survival Benefit With Bemarituzumab Plus Chemotherapy in Gastric or Gastroesophageal Junction Cancer
The addition of bemarituzumab, a first-in-class anti-FGFR2b antibody, to mFOLFOX6 chemotherapy significantly improved overall survival in patients with FGFR2b-overexpressing (≥ 10% tumor cell staining) unresectable, locally advanced or metastatic gastric or gastroesophageal junction cancer,...
Final Analysis Supports Use of Durvalumab Plus BCG Infusions in High-Risk Non–Muscle-Invasive Bladder Cancer
In patients with high-risk non–muscle-invasive bladder cancer, the addition of 1 year of the PD-L1 inhibitor durvalumab to standard induction and maintenance bacillus Calmette-Guérin (BCG) infusions led to a statistically significant and clinically meaningful improvement in disease-free survival...
Ivonescimab, a Dual-Targeting Bispecific Antibody, Improves Progression-Free Survival in Squamous NSCLC
In the phase III HARMONi-6 trial, conducted in China, the bispecific antibody ivonescimab, given with chemotherapy, improved progression-free survival by 4.2 months over the PD-1 inhibitor tislelizumab-jsgr plus chemotherapy, a 40% reduction in risk as first-line treatment of advanced squamous...
European Society for Medical Oncology Congress 2025 Meeting Highlights
The European Society for Medical Oncology (ESMO) Congress 2025 in Berlin featured many important trials with the potential to significantly influence clinical practice and improve outcomes for patients with multiple tumor types. These studies highlighted the benefits of novel treatment combination...
ASTRO Publishes First Clinical Guideline on Radiation Therapy for Gastric Cancer
A new clinical guideline from the American Society for Radiation Oncology (ASTRO) is the first to focus on radiation therapy for patients with gastric cancer. The recommendations outline radiation therapy’s role in multidisciplinary care, including best practices for patient selection, integration...
Pembrolizumab Plus Weekly Paclitaxel Improves Survival Outcomes in Platinum-Resistant Recurrent Ovarian Cancer
The addition of the PD-1 inhibitor pembrolizumab to weekly paclitaxel, with or without the VEGFA-targeted bevacizumab, significantly improved progression-free survival and overall survival in patients with platinum-resistant recurrent ovarian cancer, in the randomized, double-blind, phase III...
HER2-Positive Early Breast Cancer: Trastuzumab Deruxtecan Moves Into Earlier Clinical Settings
Two pivotal studies of fam-trastuzumab deruxtecan-nxki (T-DXd) in early HER2-positive breast cancer suggest this antibody-drug conjugate (targeting the HER2 protein) may be moving into the curative setting after having shown benefit in metastatic disease in multiple previous trials. The new...
